로딩 중…
지수 로딩 중…
Dyne Therapeutics, Inc.
DYN· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$25.24+0.24%
2026-08-03
Financials
Valuation Metrics
Dyne Therapeutics, Inc.'s Market Cap is $4.17B. At end of 2025 it was $2.51B. Ranked #1524 of 3,111 in US market (top 49%), #529 of 1,445 on NASDAQ (top 37%), #87 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 32%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.17B | US#1,524/3,111 Sec#87/269 |
| Revenue | $0.00 | US#2,980/3,111 Sec#205/269 |
| Net Income | $-519M | US—/3,111 Sec—/269 |
| Total Assets | $994M | US#2,465/3,111 Sec#102/269 |
| Net Assets | $702M | US#2,010/3,111 Sec#80/269 |
| Value | ||
| P/B | 5.94x | US#2,318/3,111 Sec#155/269 |
| FCF Yield | -11.96% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -73.97% | US#2,820/3,111 Sec#209/269 |
| ROA | -52.25% | US#2,984/3,111 Sec#223/269 |
| Financial Health | ||
| Debt Ratio | 41.57% | US#473/3,111 Sec#132/269 |
| Total Debt | $20M | US#2,732/3,111 Sec#184/269 |
| FCF | $-499M | US#2,849/3,111 Sec#262/269 |
| Cash | $676M | US#880/3,111 Sec#40/269 |
| Current Ratio | 12.02x | US#203/3,111 Sec#70/269 |
| Performance | ||
| 1Y Return | 151.14% | US#140/3,111 Sec#49/269 |
| 1M Return | 9.41% | US#248/3,111 Sec#17/269 |
| From 52W High | -3.88% | US#408/3,111 Sec#20/269 |
| 1Y MDD | -39.89% | US#1,948/3,111 Sec#144/269 |
| Trading | ||
| Volume | 2,082,790 shares | US#925/3,111 Sec#81/269 |
| Trading Value | $52M | US#1,407/3,111 Sec#91/269 |
| Per Share | ||
| EPS | $-3.47 | US—/3,111 Sec—/269 |
| BPS | $7.57 | US#1,987/3,111 Sec#94/269 |